Yulong Zheng

机构：Zhejiang Chinese Medical University, China University of Geosciences, Yancheng Institute of Technology, Hangzhou Medical College, First Affiliated Hospital Zhejiang University · ORCID：0000-0002-4035-3690

发表论文 95 篇 · 总被引 1201 次 · h-index 18

代表论文

• Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 128)
• A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial (2025 · Nature Medicine · 被引 88)
• Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial (2025 · The Lancet Oncology · 被引 61)
• Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 32)
• A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer. (2023 · Journal of Clinical Oncology · 被引 22)
• Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial (2025 · EClinicalMedicine · 被引 11)